Lexicon Pharmaceuticals Inc (LXRX)

Currency in USD
1.020
-0.050(-4.67%)
Closed·
After Hours
1.0200.000(0.00%)
·

LXRX Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.07 / -0.12
Revenue / Forecast
1.26M / 2.82M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2025--/-0.093--/6.49M----Free Sign Up
03/2025-0.07/-0.121.26M/2.82M+41.67%-55.32%Free Sign Up
12/2024-0.09/-0.1226.55M/7.16M+25%+270.81%Free Sign Up
09/2024-0.18/-0.161.75M/2.92M-12.5%-40.07%Free Sign Up
06/2024-0.17/-0.181.65M/3.44M+5.56%-52.03%Free Sign Up
03/2024-0.2/-0.21.13M/1.37M0%-17.52%Free Sign Up
12/2023-0.2/-0.22700K/1.25M+9.09%-44%Free Sign Up
09/2023-0.21/-0.21160K/2.06M0%-92.23%Free Sign Up
06/2023-0.22/-0.18320K/133.33K-22.22%+140.01%Free Sign Up
03/2023-0.17/-0.1724K/24K0%0%Free Sign Up

All numbers in USD

Lexicon Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of -$0.07 beat expectations, but revenue of $1.26M fell short of $2.82M forecast; stock declined 6.51% after hours
  • Secured $45M upfront payment from Novo Nordisk; announced positive Phase 2b results for pilavapitan in diabetic peripheral neuropathic pain
  • R&D expenses increased to $15.3M; SG&A decreased to $11.6M; net loss reduced to $25.3M from $48.4M in Q1 2024
  • Anticipates 2025 operating expenses of $135-$145M; R&D expenses projected at $100-$105M; focusing on pilavapitan and sotagliflozin programs
  • CEO emphasized commitment to pilavapitan development; CMO highlighted strategic importance of hypertrophic cardiomyopathy study
Last Updated: 13/05/2025, 23:04
Read Full Transcript

FAQ

What Is Lexicon's Earnings Per Share (TTM)?

The Lexicon EPS (TTM) is -0.51.

When Is The Next Lexicon Earnings Date?

Lexicon will release its next earnings report on 05 Aug 2025.

What Is Lexicon’s Revenue Forecasts For Upcoming Quarters?

Lexicon’s revenue forecast is 6.49M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.